US-based biopharmaceutical company Tyrogenex has completed patient enrolment in the Phase II clinical trial (APEX) of X-82 (vorolanib) for the treatment of wet age-related macular degeneration (wAMD).

X-82 is an investigational oral agent being developed to inhibit vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR).

The ability of X-82 to bind to these receptors is expected to be efficient in angiogenic diseases such as wAMD.

A total of 157 subjects have been enrolled in the Phase II trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The randomised, double-masked, placebo-controlled, dose-finding, non-inferiority APEX trial will evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wAMD.

Tyrogenex director and development senior vice-president Daniel Salazar said: "We are grateful for the commitment and enthusiasm of the scientific advisory board and the participating clinical investigators.

"We are grateful for the commitment and enthusiasm of the scientific advisory board and the participating clinical investigators."

"In addition to exceeding our initial enrolment target of 132 patients by 25 patients, we are encouraged that the data safety monitoring board has met three times so far and supported continuing the study unchanged.”

X-82 will be assessed in combination with required intravitreal anti-VEGF, compared to necessary intravitreal anti-VEGF alone in patients with neovascular AMD.

Subjects are being examined for a total of 52 weeks following the administration of one of three doses of the drug or placebo.

X-82 has been investigated in a Phase I trial in patients previously treated with Lucentis (ranibizumab), Eylea (aflibercept) and Avastin (bevacizumab) and in naïve patients, as well as currently being studied for oncology indications.

Image: Macular degeneration. Photo: courtesy of Ralf Roletschek/Wikipedia.